Indication

Triple-negative breast cancer

Aliases

Triple Negative Breast Cancer

Benchmark table

8 clinical trials

11 products

2 drugs

Clinical trial

A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma

Status: Terminated, Estimated PCD: 2023-02-13

Product

Product

Clinical trial

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Status: Recruiting, Estimated PCD: 2025-07-31

Product

Product

Clinical trial

A Phase Ib/II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer

Status: Recruiting, Estimated PCD: 2026-10-30

Product

Product

Clinical trial

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2024-08-01

Product

Clinical trial

A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Status: Completed, Estimated PCD: 2018-01-25

Product

Clinical trial

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases：a Prospective, Single-arm, Single-center Phase II Clinical Study

Status: Not yet recruiting, Estimated PCD: 2025-06-30

Product

SHR-A1921 + Bevacizumab

Clinical trial

Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy

Status: Recruiting, Estimated PCD: 2026-07-31

Product

Omnipaque 350mgI/mL

Clinical trial

A Phase II Study of Neoadjuvant QL1706 Plus Chemotherapy in Participants With High-Risk TNBC Early-Stage Breast Cancer (QUEEN-Dream)

Status: Not yet recruiting, Estimated PCD: 2025-11-07

Product

Bispecific antibody targeting PD-1 and CLTA-4

Drug

Drug